{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:30Z","timestamp":1771623690546,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403836"],"award-info":[{"award-number":["82403836"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report a well-documented case of cytokine release syndrome (CRS) following the first cycle of amivantamab combined with chemotherapy in a patient with osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC), highlighting its diagnosis, management, and association with a rapid antitumor response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 72-year-old man with metastatic lung adenocarcinoma (epidermal growth factor receptor (EGFR) exon 19 del) progressing on osimertinib initiated treatment with amivantamab, pemetrexed, and carboplatin. Five days post-infusion, he developed a persistent fever unresponsive to broad-spectrum antibiotics. Infection was rigorously excluded based on normal procalcitonin, undetectable endotoxin, and negative cultures. In contrast, inflammatory markers were elevated (peak CRP (C\u2212reactive protein) 16.6 mg\/dL), and cytokine profiling revealed significant elevations in IL\u22126 (interleukin\u22126) (107 pg\/mL), sIL-2R (soluble interleukin\u22122 receptor), TNF-\u03b1 (tumor necrosis factor\u2212alpha), and IL-10, accompanied by profound lymphopenia. A computed tomography (CT) scan demonstrated a significant tumor reduction. A diagnosis of grade 1 CRS (by ASTCT (American Society for Transplantation and Cellular Therapy) criteria) was made. The fever and inflammatory markers resolved with supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>This case provides comprehensive clinical and serological evidence of amivantamab-chemotherapy-induced CRS. The temporal association between the robust cytokine surge, characteristic of T-cell activation, and the observed rapid tumor regression suggests that the same immunologic mechanism likely underpinned both the efficacy and the toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CRS is an important adverse event associated with amivantamab-based combination therapy in solid tumors. Early recognition, based on clinical\u00a0suspicion and characteristic cytokine profiles, and differentiation from infection are crucial. The concurrent rapid tumor response indicates that effective immune activation drives both toxicity and efficacy, underscoring the need for optimal management strategies to mitigate CRS without compromising antitumor activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1758359","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:04Z","timestamp":1768800484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: The double-edged sword: cytokine release syndrome and rapid tumor response in a patient treated with amivantamab and chemotherapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Pengfei","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guannan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The 983rd Hospital of the People's Liberation Army","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueguang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haili","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/cancers17040563","article-title":"Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene","volume":"17","author":"Nico\u015b","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"B6","volume-title":"Multi-discipline review: NDA\/BLA 761210 (RYBREVANT, amivantamab-vmjw) (Application number: 761210Orig1s000)","year":"2021"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003003","article-title":"FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone","volume":"87","author":"Hassan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051875","article-title":"TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome","volume":"13","author":"Carrara","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.010","article-title":"Five cases of cytokine release syndrome in patients receiving cytotoxic chemotherapy together with nivolumab plus ipilimumab: A case report","volume":"19","author":"Shiraishi","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2018.07.016","article-title":"A radiologist\u2019s guide to response evaluation criteria in solid tumors","volume":"48","author":"Lalchandani","year":"2019","journal-title":"Curr Probl Diagn Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1182\/blood-2024-193916","article-title":"Cytokine release syndrome: trends with T cell engaging bispecifics from a systematic review of licensing applications","volume":"144","author":"Radtke","year":"2024","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7983","article-title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","volume":"8","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1758359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:06Z","timestamp":1768800486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1758359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1758359"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1758359","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1758359"}}